VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction

VBI Vaccines (NASDAQ:VBIV; TSX:VBV) announced a company’s abstract has been selected as a “Presidential Poster of Distinction” for presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
As quoted in the press release:

Dr. Francisco Diaz-Mitoma, M.D., Ph.D., VBI’s Chief Medical Officer, will present the poster, which highlights data from the company’s open label, Phase IV clinical study in which 91 healthy, adult volunteers aged 20 to 40 received 10 mg/mL of VBI’s third-generation Hepatitis B (HBV) vaccine, Sci-B-Vac. Immunization with Sci-B-Vac resulted in rapid seroprotection after two Sci-B-Vac vaccinations, and high anti-hepatitis B surface antigen (HBsAg) geometric mean titers (GMTs). Moreover, the majority of the participants with high GMTs also possessed antibody responses against the HBsAg Pre-S1 and Pre-S2 domains.
Preliminary data highlights the utility of the inclusion of pre-S1 and pre-S2 antigens and suggests a significant contribution of the Pre-S domains to the rapid kinetics and protective titer of antibodies against HBsAg, which may correlate with improved immunogenicity.

Click here to read the full press release.

Source: www.marketwired.com